Security Snapshot

Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) Institutional Ownership

CUSIP: 75915K309

13F Institutional Holders and Ownership History from Q2 2022 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$8.20

Save this security research path

Keep this CUSIP in your research flow, then return after the next filing cycle to check what changed.

Create free account to save this research Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
RGLS
Shares outstanding
66,505,186
Price per share
$8.20
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-84,477
Value change
-$132,628
Number of holders
0
Price from insider filings
$8.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 75915K309.
  • 0 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 0 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 75915K309?
CUSIP 75915K309 identifies RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 3.9% $9,086,956 2,696,426 Vivo Opportunity Fund Holdings, L.P. 31 Mar 2025
Point72 Asset Management, L.P. 0.3% -93% $1,977,487 -$30,197,722 241,157 -94% Point72 Asset Management, L.P. 30 Jun 2025

Institutional Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$132,628 $8.20 0
2025 Q3 $8.20 0
2025 Q2 0 $0 -$105,304,835 $8.16 0
2025 Q1 53,596,381 $105,311,940 +$3,105,761 $1.75 74
2024 Q4 53,508,570 $84,543,374 -$5,126,517 $1.58 68
2024 Q3 56,729,933 $89,079,771 +$3,280,059 $1.57 69
2024 Q2 54,841,321 $97,892,529 +$13,518,084 $1.78 60
2024 Q1 45,620,114 $128,657,473 +$103,077,800 $2.88 42
2023 Q4 9,168,367 $11,735,268 +$40,056 $1.28 23
2023 Q3 8,956,428 $12,343,312 +$1,002,811 $1.37 22
2023 Q2 8,228,751 $12,096,772 +$2,407,893 $1.47 21
2023 Q1 6,598,665 $5,593,075 -$77,466 $0.85 22
2022 Q4 6,670,905 $9,138,408 -$4,945 $1.37 21
2022 Q3 6,668,921 $11,336,000 +$3,422,009 $1.70 19
2022 Q2 4,622,322 $9,565,000 +$9,565,000 $2.06 22

Sponsored